mAbs, Nibs und Co. bei entzündlichen rheumatischen Erkrankungen

Elisabeth Deibel, Lukas Wildi

Referenzen

8. Chi Zhang MD , Zhao Wu PhD , Jia-Wen Li MD , Hong Zhao PhD , Gui-Qiang Wang MD , The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality, *International Journal of Antimicrobial Agents* (2020), doi
